Advertisement
Australia markets closed
  • ALL ORDS

    8,013.80
    +11.00 (+0.14%)
     
  • ASX 200

    7,767.50
    +7.90 (+0.10%)
     
  • AUD/USD

    0.6669
    +0.0018 (+0.27%)
     
  • OIL

    81.46
    -0.28 (-0.34%)
     
  • GOLD

    2,336.90
    +0.30 (+0.01%)
     
  • Bitcoin AUD

    91,084.76
    +908.70 (+1.01%)
     
  • CMC Crypto 200

    1,266.05
    -17.78 (-1.38%)
     
  • AUD/EUR

    0.6221
    +0.0015 (+0.24%)
     
  • AUD/NZD

    1.0950
    +0.0023 (+0.21%)
     
  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     
  • NASDAQ

    19,682.87
    -106.16 (-0.54%)
     
  • FTSE

    8,164.12
    -15.56 (-0.19%)
     
  • Dow Jones

    39,118.86
    -45.20 (-0.12%)
     
  • DAX

    18,235.45
    +24.90 (+0.14%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval

Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval

Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded from 68 to 95 Monday. The biotech soared 30% Friday on positive news on its Duchenne Muscular Dystrophy gene therapy. Decades of market research shows that the best stocks often have an 80 or better RS Rating as they begin their biggest runs.